Curis Inc. (NASDAQ:CRIS) received a $7.00 price target from stock analysts at RBC Capital Markets in a report released on Wednesday. The firm currently has a a “buy” rating on the stock. RBC Capital Markets’ target price would suggest a potential upside of 139.73% from the stock’s current price.
Several other equities analysts have also recently weighed in on CRIS. Zacks Investment Research raised shares of Curis from a “sell” rating to a “hold” rating in a research note on Thursday, June 16th. Robert W. Baird reissued an “outperform” rating and issued a $7.00 target price on shares of Curis in a research note on Wednesday, September 7th. Finally, FBR & Co reissued a “buy” rating on shares of Curis in a research note on Thursday, September 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $5.05.
Curis (NASDAQ:CRIS) opened at 2.92 on Wednesday. Curis has a 52 week low of $1.25 and a 52 week high of $3.42. The stock has a 50 day moving average of $2.29 and a 200-day moving average of $1.88. The firm’s market cap is $378.06 million.
Curis (NASDAQ:CRIS) last released its earnings results on Thursday, August 4th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Curis had a negative net margin of 526.72% and a negative return on equity of 65.51%. The business earned $1.70 million during the quarter, compared to analysts’ expectations of $2.05 million. During the same period last year, the business earned ($0.06) earnings per share. The firm’s revenue was down 19.0% on a year-over-year basis. Analysts expect that Curis will post ($0.37) earnings per share for the current year.
In other Curis news, major shareholder Discovery Technologie Aurigene purchased 10,208,333 shares of the company’s stock in a transaction on Wednesday, September 7th. The shares were purchased at an average cost of $2.40 per share, with a total value of $24,499,999.20. Following the completion of the purchase, the insider now owns 27,328,464 shares in the company, valued at $65,588,313.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 6.09% of the stock is owned by company insiders.
A number of institutional investors have recently modified their holdings of the stock. Barclays PLC raised its position in shares of Curis by 10,149.4% in the second quarter. Barclays PLC now owns 64,059 shares of the company’s stock valued at $100,000 after buying an additional 63,434 shares during the period. Metropolitan Life Insurance Co. NY acquired a new position in shares of Curis during the second quarter valued at about $146,000. ProShare Advisors LLC raised its position in shares of Curis by 1.3% in the second quarter. ProShare Advisors LLC now owns 109,812 shares of the company’s stock valued at $171,000 after buying an additional 1,418 shares during the period. Rhumbline Advisers raised its position in shares of Curis by 27.2% in the second quarter. Rhumbline Advisers now owns 138,986 shares of the company’s stock valued at $217,000 after buying an additional 29,751 shares during the period. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of Curis during the first quarter valued at about $248,000. 52.36% of the stock is currently owned by hedge funds and other institutional investors.